Triple‐negative breast cancer (TNBC), a high degree of malignancy, spatial transcriptomic, and single‐cell RNA sequencing data analyses revealed that the activation of TLR4 in tumor cells enhances the drug responsiveness [163, 164]. The gene discussed is TLR4; the disease is neoplasm.